Cabazitaxel is microtubule inhibitor indicated in combination with prednisone for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign Out
